CA2065346C - Recepteurs .alpha. et .beta. de facteur de necrose tumorale - Google Patents

Recepteurs .alpha. et .beta. de facteur de necrose tumorale Download PDF

Info

Publication number
CA2065346C
CA2065346C CA002065346A CA2065346A CA2065346C CA 2065346 C CA2065346 C CA 2065346C CA 002065346 A CA002065346 A CA 002065346A CA 2065346 A CA2065346 A CA 2065346A CA 2065346 C CA2065346 C CA 2065346C
Authority
CA
Canada
Prior art keywords
amino acids
protein
sequence
tnf
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA002065346A
Other languages
English (en)
Other versions
CA2065346A1 (fr
Inventor
Craig A. Smith
Raymond G. Goodwin
M. Patricia Beckmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunex Corp
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corp filed Critical Immunex Corp
Priority to CA002485553A priority Critical patent/CA2485553A1/fr
Publication of CA2065346A1 publication Critical patent/CA2065346A1/fr
Application granted granted Critical
Publication of CA2065346C publication Critical patent/CA2065346C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Toxicology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002065346A 1989-09-05 1990-07-17 Recepteurs .alpha. et .beta. de facteur de necrose tumorale Expired - Lifetime CA2065346C (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002485553A CA2485553A1 (fr) 1989-09-05 1990-07-17 Recepteurs .alpha. et .beta. de facteur de necrose tumorale

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US405,370 1982-08-05
US40324189A 1989-09-05 1989-09-05
US403,241 1989-09-05
US40537089A 1989-09-11 1989-09-11
US42141789A 1989-10-13 1989-10-13
US421,417 1989-10-13
PCT/US1990/004001 WO1991003553A1 (fr) 1989-09-05 1990-07-17 RECEPTEURS DES FACTEURS NECROSE TUMORALE α et $g(b)

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA002485553A Division CA2485553A1 (fr) 1989-09-05 1990-07-17 Recepteurs .alpha. et .beta. de facteur de necrose tumorale

Publications (2)

Publication Number Publication Date
CA2065346A1 CA2065346A1 (fr) 1991-03-06
CA2065346C true CA2065346C (fr) 2005-03-29

Family

ID=46201946

Family Applications (2)

Application Number Title Priority Date Filing Date
CA002065346A Expired - Lifetime CA2065346C (fr) 1989-09-05 1990-07-17 Recepteurs .alpha. et .beta. de facteur de necrose tumorale
CA002485553A Expired - Lifetime CA2485553A1 (fr) 1989-09-05 1990-07-17 Recepteurs .alpha. et .beta. de facteur de necrose tumorale

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA002485553A Expired - Lifetime CA2485553A1 (fr) 1989-09-05 1990-07-17 Recepteurs .alpha. et .beta. de facteur de necrose tumorale

Country Status (3)

Country Link
AU (1) AU630497B2 (fr)
CA (2) CA2065346C (fr)
WO (1) WO1991003553A1 (fr)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7264944B1 (en) 1989-04-21 2007-09-04 Amgen Inc. TNF receptors, TNF binding proteins and DNAs coding for them
US6221675B1 (en) 1989-04-21 2001-04-24 Amgen, Inc. TNF receptors, TNF binding proteins and DNAs coding for them
DE59010941D1 (de) * 1989-04-21 2005-03-24 Amgen Inc TNF-Rezeptor, TNF bindende Proteine und dafür kodierende DNAs
IL95031A (en) 1989-07-18 2007-03-08 Amgen Inc Method for the production of a human recombinant tumor necrosis factor inhibitor
US6143866A (en) * 1989-07-18 2000-11-07 Amgen, Inc. Tumor necrosis factor (TNF) inhibitor and method for obtaining the same
DE59010908D1 (de) 1989-09-12 2000-08-10 Hoffmann La Roche TNF-bindende Proteine
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
AU646695B2 (en) * 1990-04-09 1994-03-03 Immunex Corporation Isolated viral protein cytokine antagonists
WO1993006128A1 (fr) * 1991-09-16 1993-04-01 Peptide Technology Limited Peptides antagonistes du facteur de necrose tumorale
EP0611302B1 (fr) * 1991-10-15 2000-03-29 MULLARKEY, Michael F. Recepteurs pour le traitement des troubles inflammatoires de phase tardive
NZ256293A (en) * 1992-09-15 1997-06-24 Immunex Corp Method of treating tumour necrosis factor - mediated inflammation by use of tnf antagonist
NZ263102A (en) * 1993-03-19 1997-05-26 Immunex Corp Pharmaceutical compositions comprising a ligand protein such as interleukin-4 and a soluble receptor protein that binds thereto
NZ278607A (en) * 1994-02-07 1999-05-28 Knoll Ag Use of tnf antagonists for treating disorders involving elevated serum levels of il-6 wherein the serum levels are 500pg/ml or above
WO1997028828A1 (fr) 1996-02-09 1997-08-14 Amgen Boulder Inc. Composition comprenant un inhibiteur de l'interleukine 1 et un polymere a liberation controlee
TW555765B (en) 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
CA2273852C (fr) 1996-12-06 2009-09-29 Amgen Inc. Therapie combinee utilisant un inhibiteur de l'il-1 pour traiter les maladies induites par l'il-1
ATE247974T1 (de) 1996-12-06 2003-09-15 Amgen Inc Kombinationtherapie mit einem tnf-bindendem protein zür behandlung von durch tnf verursachten erkrangungen
US6893838B1 (en) 1998-04-07 2005-05-17 Genetics Institute Llc DADD, death activator death domain protein
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US7041474B2 (en) * 1998-12-30 2006-05-09 Millennium Pharmaceuticals, Inc. Nucleic acid encoding human tango 509
US20080213778A1 (en) 1998-12-30 2008-09-04 Millennium Pharmaceuticals, Inc. Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic, and other uses
HK1045715B (zh) * 1999-05-10 2005-06-03 中外制药株式会社 培养细胞的方法
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
PT2990420T (pt) 2000-05-26 2017-03-16 Immunex Corp Uso de anticorpos de recetor de interleucina-4 e composições dos mesmos
TR201809678T4 (tr) 2001-06-26 2018-07-23 Amgen Fremont Inc Opgl ye karşi antikorlar.
US9028822B2 (en) 2002-06-28 2015-05-12 Domantis Limited Antagonists against TNFR1 and methods of use therefor
US20040131614A1 (en) 2002-07-19 2004-07-08 Abbott Biotechnology Ltd. Treatment of pulmonary disorders using TNFalpha inhibitor
TWI439284B (zh) 2004-04-09 2014-06-01 艾伯維生物技術有限責任公司 用於治療ＴＮＦα相關失調症之多重可變劑量療法
GB0414054D0 (en) 2004-06-23 2004-07-28 Owen Mumford Ltd Improvements relating to automatic injection devices
JP5757495B2 (ja) 2005-05-16 2015-07-29 アッヴィ バイオテクノロジー リミテッド びらん性多発性関節炎の治療のためのｔｎｆ阻害剤の使用
US20070041905A1 (en) 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
TW201337266A (zh) 2005-11-01 2013-09-16 Abbott Biotech Ltd 利用生物標記診斷關節黏連脊椎炎之方法及組合物
US8007790B2 (en) 2006-04-03 2011-08-30 Stowers Institute For Medical Research Methods for treating polycystic kidney disease (PKD) or other cyst forming diseases
EP2666478A3 (fr) 2006-04-10 2014-10-22 AbbVie Biotechnology Ltd Utilisations et compositions pour le traitement du psoriasis
WO2008063213A2 (fr) 2006-04-10 2008-05-29 Abbott Biotechnology Ltd. Compositions destinées au traitement de la polyarthrite psoriasique et leurs applications
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
CA2564435A1 (fr) 2006-04-10 2007-10-10 Abbott Biotechnology Ltd. Methodes de controle et de traitement des troubles intestinaux
CN103316402A (zh) 2006-06-30 2013-09-25 艾伯维生物技术有限公司 自动注射装置
JP2010501623A (ja) 2006-08-28 2010-01-21 アレス トレーディング ソシエテ アノニム Ｆｃ含有タンパク質の精製法
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
EP2165194A4 (fr) 2007-05-31 2010-09-08 Abbott Lab BIOMARQUEURS PRÉDICTIFS DE LA RÉACTIVITÉ AUX INHIBITEURS TNF-alpha DANS DES TROUBLES AUTO-IMMUNS
EP2171451A4 (fr) 2007-06-11 2011-12-07 Abbott Biotech Ltd Procédés de traitement de l'arthrite idiopathique juvénile
EP2384367A4 (fr) 2008-12-30 2013-07-10 Janssen Biotech Inc Marqueurs sériques prédisant la réponse clinique à des anticorps anti-tnf chez les patients souffrant de spondylarthrite ankylosante
AU2010242972B2 (en) 2009-04-29 2015-07-09 Abbvie Biotechnology Ltd Automatic injection device
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
US20110150891A1 (en) 2009-12-16 2011-06-23 Philip Bosch Methods of Treating Interstitial Cystitis
SI2523688T1 (en) 2010-01-15 2018-03-30 Kirin-Amgen, Inc. Formulation of antibodies and therapeutic regimes
JP2013518590A (ja) 2010-02-02 2013-05-23 アボツト・バイオテクノロジー・リミテツド ＴＮＦ−α阻害剤を用いる処置に対する応答性を予測するための方法および組成物
KR102071212B1 (ko) 2010-04-21 2020-01-30 애브비 바이오테크놀로지 리미티드 치료제의 제어된 전달을 위한 착용형 자동 주사 디바이스
US20110287018A1 (en) 2010-05-19 2011-11-24 Philip Bosch Methods of Treating Interstitial Cystitis
MX2012014080A (es) 2010-06-03 2013-05-01 Abbvie Biotechnology Ltd Usos y composiciones para el tratamiento de hidradenitis superativa (hs).
EP2490024A1 (fr) 2010-12-22 2012-08-22 Proteomika, S.L. Procédé pour optimiser le traitement de patients au moyen de médicaments biologiques
SG192119A1 (en) 2011-01-24 2013-08-30 Abbvie Biotechnology Ltd Automatic injection devices having overmolded gripping surfaces
US20120233834A1 (en) 2011-03-18 2012-09-20 Abbott Biotechnology Ltd. Systems, devices and methods for assembling automatic injection devices and sub-assemblies thereof
CA2831563A1 (fr) 2011-03-29 2012-10-04 Abbvie Inc. Deploiement d'enveloppe ameliore dans des dispositifs d'injection automatique
US9956345B2 (en) 2011-04-21 2018-05-01 Abbvie Inc. Wearable automatic injection device for controlled administration of therapeutic agents
US20140234330A1 (en) 2011-07-22 2014-08-21 Amgen Inc. Il-17 receptor a is required for il-17c biology
JP2016511747A (ja) 2013-01-04 2016-04-21 マサチューセッツ インスティテュート オブ テクノロジー ナノ粒子表面結合に基づく薬物の組織への送達
KR102530900B1 (ko) 2014-03-31 2023-05-12 암젠 케이-에이, 인크. 손발톱 및 두피 건선의 치료 방법
CA2970577A1 (fr) 2014-12-22 2016-06-30 Ares Trading S.A. Composition pharmaceutique liquide
JP2019513737A (ja) 2016-04-08 2019-05-30 ギリアード サイエンシーズ， インコーポレイテッド がん、炎症性疾患および自己免疫疾患を処置するための組成物および方法
CA3045944A1 (fr) 2016-12-07 2018-06-14 Progenity, Inc. Procedes, dispositifs et systemes de detection du tractus gastro-intestinal
AU2017378393B2 (en) 2016-12-14 2023-03-09 Bt Bidco, Inc. Treatment of a disease of the gastrointestinal tract with a TNF inhibitor
JOP20190162A1 (ar) 2016-12-30 2019-06-27 Biocad Joint Stock Co تركيبة صيدلانية مائية من جسم مضاد لـ tnf? أحادي النسيلة معاود الارتباط الجيني
US20230312700A1 (en) 2018-06-20 2023-10-05 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a tnf inhibitor
JP2021529780A (ja) 2018-07-03 2021-11-04 ノバルティス アーゲー Ｎｌｒｐ３アンタゴニストを使用するｔｎｆ阻害剤に対して抵抗性の対象のための治療の方法又は治療を選択する方法
JP2022505562A (ja) 2018-10-24 2022-01-14 ノバルティス アーゲー Ｎｌｒｐ活性に関連する状態を治療するための化合物及び組成物
CN113015730A (zh) 2018-11-13 2021-06-22 诺华股份有限公司 用于治疗与nlrp活性相关的病症的化合物和组合物
CN113166081A (zh) 2018-11-13 2021-07-23 诺华股份有限公司 用于治疗与nlrp活性相关的病症的化合物和组合物
CN113348011B (zh) 2018-11-19 2023-04-18 比奥拉治疗股份有限公司 用生物治疗剂治疗疾病的方法和装置
US20220227707A1 (en) 2019-01-22 2022-07-21 Novartis Ag Compounds and compositions for treating conditions associated with nlrp activity
WO2021002887A1 (fr) 2019-07-02 2021-01-07 Novartis Inflammasome Research, Inc. Antagonistes de nlrp3 ciblant l'intestin et leur utilisation en thérapie
CN121197633A (zh) 2019-12-13 2025-12-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
JP2025531789A (ja) 2022-09-07 2025-09-25 エムディーエックス マネージメント エルエルシー がん治療のためのｓｈｐ－１阻害剤
CN120916767A (zh) 2022-11-02 2025-11-07 Mdx管理有限责任公司 用于治疗癌症的酪氨酸激酶抑制剂和促炎剂的组合
EP4680215A1 (fr) 2023-03-17 2026-01-21 MDX Management LLC Compositions et méthodes visant à atténuer les effets indésirables de thérapies
CN122029273A (zh) 2023-08-16 2026-05-12 Mdx管理有限责任公司 用于激活免疫细胞的组合物和方法
AR133647A1 (es) 2023-08-25 2025-10-22 Proteologix Us Inc Constructos de anticuerpos multiespecíficos anti-il-13 y usos de los mismos
WO2025188921A1 (fr) 2024-03-06 2025-09-12 Mdx Management Llc Inhibiteurs de shp-1 et activateurs de lymphocytes t

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL83878A (en) * 1987-09-13 1995-07-31 Yeda Res & Dev Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it
GB8806339D0 (en) * 1988-03-17 1988-04-13 Hoffmann La Roche Monoclonal antibodies
GB8807803D0 (en) * 1988-03-31 1988-05-05 Glaxo Group Ltd Biochemical product

Also Published As

Publication number Publication date
CA2065346A1 (fr) 1991-03-06
AU6178190A (en) 1991-04-08
CA2485553A1 (fr) 1991-03-21
WO1991003553A1 (fr) 1991-03-21
AU630497B2 (en) 1992-10-29

Similar Documents

Publication Publication Date Title
EP0418014B1 (fr) Récepteurs pour le facteur de nécrose de tumeur alpha et beta
US7459528B2 (en) Glycoproteins which bind to TNF
AU630497B2 (en) Tumor necrosis factor-alpha and -beta receptors
US5945397A (en) Purified p75 (type II) tumor necrosis factor receptor polypeptides
US5605690A (en) Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
AU670125B2 (en) Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists
AU647566B2 (en) Leukemia inhibitory factor receptors
EP0604418B1 (fr) Antagonistes de cytokines a base de proteines virales isolees
US20060275868A1 (en) Fusion proteins comprising tumor necrosis factor receptor
US5264416A (en) Interleukin-7 receptors
FI105099B (fi) Menetelmä biologisesti aktiivisen nisäkkään kasvainkuoliotekijäreseptoriproteiinin valmistamiseksi ja tätä koodittava DNA-sekvenssi
IE911108A1 (en) Isolated Viral Protein Cytokine Antagonists

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry